[A study of pharmacokinetics of cefoperazone in children].
A study of the pharmacokinetics of cefoperazone (CPZ), used as the sole antibiotic, was performed in 17 children and neonates. The types of infections treated were 7 UTI, 2 otitis media, 2 RTI, 4 septicemia or severe neonatal infections. Causative bacteria included 6 E. coli, 3 Pseudomonas aeruginosa, 1 C perfringens, 1 Klebsiella pneumoniae and 2 Staphylococcus aureus. Cefoperazone was administered by means of rapid IV injections (over 5 min) or IV infusions BID. The blood samples were taken by means of capillary microtubes at time 0, 0.25, 0.50, 0.75, 1, 2, 4, 6, 8 and 12 hours after the end of the first injection. After centrifugation and freezing at -80 degrees DEG method using modified Difco M2 Agar (Nall plus sodium citrate) and stock organinism Bacillus subtilis Atcc 6633. The results achieved in children and neonates were compared, in the 11 children (mean age 6.5 years). The mean single dose was 53 mg/kg. The mean maxima concentration was 145 mcg/ml and was obtained at 0.5 h. Mean serum half-life is 2.4 h. For the neonates mean age was 16 days and the dosage was 47 mg/kg, the maxima concentration was 232 micrograms/ml and was obtained at 0.6 h. The mean serum half-life was 3.4 h in the 2 groups, serum levels at 12 h were still high with a mean of 6.2 micrograms/ml for the 17 children. It appears that doses of 25-50 mg/kg given BID would be satisfactory.
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy; D002438:Cefoperazone / Q000378:metabolism* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000378:metabolism; D007700:Kinetics; D008297:Male
D002438:Cefoperazone
Etude pharmacocinétique de la céfopérazone chez l'enfant.